At the Association of Biomolecular Research Facilities annual meeting this week, the ABRF Genomics Research Group presented results from its comparison of single-cell RNA sequencing platforms.
The two studies used Drop-seq RNA profiling to discover essentially all cell types and establish cell lineages in a model organism flatworm.
The company said PerkinElmer will pay A$.28 per share for its 89.9 million outstanding shares, a 100 percent premium to RHS's Feb. 23 closing price on the ASX.
Scientists at Helmholtz Zentrum München have developed a new package called Scanpy that they hope will support major analytical efforts, such as the Human Cell Atlas.
The company plans to launch a single-cell CNV assay, a single cell ATAC-seq assay, and a single-cell feature barcoding assay later this year.
Paris-based Scipio will use the seed funding to further develop and commercialize its first prototype kit for single-cell transcriptomics.
Fluidigm said that Q3 mass cytometry product revenue more than doubled to $10.3 million from $5.1 million in the year-ago period.
Such an atlas could enable investigators to understand how genetic variants impact disease risk, define drug toxicities, improve therapies, and advance regenerative medicine.
In Science this week: ancient Neanderthal and human genomes, and more.
The UK-based company plans to use the funds to develop an automated, benchtop device for the creation of high-value, genome-edited cell lines.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.